Fluidigm Announces the Collaboration with Icahn School of Medicine

Fluidigm Announces the Collaboration with Icahn School of Medicine

Fluidigm announces to be a partner with Mount Sinai School of Medicine for the project that leads to the detection of Epigenetic Markers of WMD Exposure. In regard to the project for developing Epigenetic signatures that would identify exposure to weapons of mass destruction, Fluidigm announces the collaboration with Icahn School of Medicine at Mount Sinai.

The estimated funding for this overall project is $27.8 million which is led by the US Defence Department’s Defence Advanced Researched Projects Agency (DARPA). This agency is a part of Epigenetic Characterization and Observation (ECHO) program, whose aims are to develop new approaches to analyze epigenetic markers and new instrumentation that can be used in the field by operators with minimal training.

According to its estimated study, till four years, it will receive $3.9 million to develop a microfluidic device for single-cell measurement of epigenetic changes, says Fluidigm.

The main aim of the project is to develop an assay that would be frequently detecting the exposure of military troops to threatening agents in the future days so that required steps can be taken on time. This statement was made by Stuart Sealfon, who is the Director of the Centre for Advanced Research on Diagnostic Assays at Icahn School of Medicine and is also the principal investigator of the study.

Sealfon also added in his statement that, as individual cells would be responding to agents in various ways, so they will use the single-cell analysis to identify the novel epigenetic signatures. Fluidigm’s microfluidic assay expertise is shown in C1, Biomark, and Polaris instruments are the perfect duo for the mentioned research program.

Chris Linthwaite, the President and the CEO of Fluidigm states that this following collaboration will allow Fluidigm to grow for the advanced development of its microfluidics technologies. This technology will expand the boundaries for new applications and systems for epigenetics. Moreover, it will further help in flourishing into new markets, where currently they don’t stand.

Share this post